The invention relates to isoquinoline derivatives having the general Formula (I) wherein X is O, S or NH； Y is OH or NH<；SUB>；2<；/SUB>；； m is 0, 1 or 2； n is 1 or 2； R<；SUB>；1<；/SUB>； is H, when Y is NH<；SUB>；2<；/SUB>；； or R<；SUB>；1<；/SUB>； is H, (C<；SUB>；1-4<；/SUB>；)alkyl or halogen, when Y is OH； R<；SUB>；2<；/SUB>； and R<；SUB>；3<；/SUB>； are independently H, (C<；SUB>；1-4<；/SUB>；)alkyl or halogen； R is H or (C<；SUB>；1-6<；/SUB>；)alkyl, optionally substituted with OH, (C<；SUB>；1-4<；/SUB>；)- alkyloxy, (C<；SUB>；1-4<；/SUB>；)alkyloxycarbonyl, (C<；SUB>；3-7<；/SUB>；)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C<；SUB>；6-10<；/SUB>；)aryl, (C<；SUB>；6-10<；/SUB>；)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C<；SUB>；1-4<；/SUB>；)alkyl, (C<；SUB>；1-4<；/SUB>；)alkyloxy, (C<；SUB>；1-4<；/SUB>；)alkylsulfonyl and halogen； or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.
